MedTrace Logo

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

NCT00858208 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2012-04-11

Study results available
· View outcomes & findings →

Summary

Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

pegaptanib sodium

pegaptanib sodium intravitreal injection every 6 weeks for 2 years

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00858208 on ClinicalTrials.gov